|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Capture, manage, analyze, and mine chemical data and information with advanced cheminformatics technology.
Welcome to the ICBS Discovery e-NewsBrief from the International Chemical Biology Society. This is a free, bi-weekly digest of headlines and news related to the chemical biology field. With a variety of stories selected from media outlets around the world, we hope you will find this publication informative. The e-NewsBrief will arrive in your email inbox every other Thursday.
The International Chemical Biology Society is a nonprofit organization dedicated to promoting research and educational opportunities at the interface of chemistry and biology. Join Today!
Save the Date! ICBS2014 San Francisco, Nov. 17 – 19. Now accepting poster abstract submissions.
Faster, cheaper tests for sickle cell disease
Researchers have developed a new test for sickle cell disease that provides results in 12 minutes and costs as little as 50 cents — far faster and cheaper than other tests. The test is described in a paper published recently in the Proceedings of the National Academy of Sciences.
Study: Drug 20 percent more effective than ACE inhibitors for heart failure
Medical News Today
For treating patients with chronic heart failure, ACE inhibitors are usually the first port of call. But a new study claims an experimental drug called LCZ696 performs around 20 percent better than ACE inhibitors when it comes to reducing rates of hospitalizations and deaths due to chronic heart failure.
Finding keys to glioblastoma therapeutic resistance
Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas — the primary form of a deadly brain cancer — are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.
New drug is first to work in the gut to target Crohn's disease symptoms
A new drug could bring relief for those who have the serious bowel disorder Crohn's disease. Vedolizumab is the first to work directly in the gut lining, targeting the inflammation that causes chronic symptoms such as diarrhoea, bleeding and fatigue. In trials, 40 percent of patients were free of symptoms for at least a year — with healing of the gut lining in some cases.
Experimental Ebola drug cured 100 percent of monkeys tested
In what scientists are calling a "monumental achievement," an experimental medication called ZMapp — given on a compassionate basis to a handful of Ebola victims in the current outbreak — cured 100 percent of monkeys treated in a Canadian study, researchers announced. The drug is in the early stage of development and has never been formally tested in humans. In a study published in the journal Nature, however, the drug allowed all 18 rhesus macaques infected with a lethal dose of Ebola to recover.
Non-invasive prostate cancer blood test simplifies outdated PSA tests
A new method for detecting prostate cancer could eliminate the need for inefficient protein specific antigen tests, which have been used for decades as the primary way to screen for the disease. New research from the Guangdong Medical College in China suggests a laser-based approach could be the latest breakthrough in prostate cancer detection.
New way to diagnose malaria by detecting parasite's waste
A technique that can detect malarial parasite's waste in infected blood cells has been developed by researchers. "There is real potential to make this into a field-deployable system, especially since you don't need any kind of labels or dye. It's based on a naturally occurring biomarker that does not require any biochemical processing of samples" says one of the senior authors of a paper.
War between bacteria, phages benefits humans
In our battle with cholera bacteria, we may have an unknown ally in bacteria-killing viruses known as phages. Researchers report that phages can force cholera bacteria, even during active infection in humans, to give up their virulence in order to survive.
Ebola genomes sequenced
Responding rapidly to the deadly outbreak of Ebola virus disease in West Africa, a team of researchers has sequenced and analyzed many Ebola virus genomes. Their findings could have important implications for rapid field diagnostic tests. The researchers hope their results will speed up scientific understanding of the epidemic and assist global efforts to contain it.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063